Please assess the completion status of the following clinical trial:

Trial Title: Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective colon and rectal cancer surgery with primary anastomosis~* Or elective colorectal surgery for suspected carcinoma~* No evidence of distant metastases (preoperative CT-abdomen and X-thorax or CTthorax)~* Procedure either with or without diverting stoma~* Both laparoscopic and open surgery~* Informed consent~* Aged 18 years or older~Exclusion Criteria:~* Previous colorectal malignancy~* Current malignancy which is now undergoing treatment~* Inflammatory bowel disease (Crohn's disease or ulcerative colitis)~* Previous surgery for diverticular disease~* Performance status ASA 4 or higher (American Society for Anaesthesiologists)~* Expected adverse reactions/allergies for study medication~* Prednisone use \> 5 mg per day~* Familial adenomatous polyposis coli (FAP; Lynch syndrome), Hereditary Non Polyposis Colorectal Cancer (HNPCC)~* Mental disorder/unable to give informed consent~* Pregnancy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard treatment (Type: NO_INTERVENTION): Standard treatment for colorectal cancer
- Selective decontamination of the digestive tract (SDD) (Type: EXPERIMENTAL): Standard treatment + SDD perioperatively 4 times daily 10 ml of SDD suspension, consisting of 100mg colistin sulfate, 80mg tobramycin and 500mg of amphotericin B.~SDD treatment starts 3 days before surgery and is continued until at least 3 days postoperatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).